Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :54
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal


Year : 2021  |  Volume : 58  |  Issue : 1  |  Page : 91-95

Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment

1 Department of Internal Medicine and Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey
2 Department of Neurosurgery, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
3 Department of Radiology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
4 Department of Radiation Oncology, Medstar Antalya Hospital, Antalya, Turkey
5 Department of Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey

Correspondence Address:
Ozlem Nuray Sever
Department of Internal Medicine and Medical Oncology, Gaziantep University School of Medicine, Gaziantep
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_758_18

Rights and Permissions

Background: Treatment options for recurrent glioblastoma (GBM) have limited efficacy. Although reoperation is useful for both the confirmation of the diagnosis of recurring disease and the relief of the symptoms, its effect on survival is unknown. The aim of this study was to evaulate the impact of second surgery in recurrent GBM. Methods: Patients with GBM followed in our center between January 2015 and April 2018 were analyzed retrospectively based on the treatment options. Results: 25 patients diagnosed with recurrent GBM were analyzed. Ten patients (40%) were treated with chemotherapy following reoperation, and 15 patients (60%) were treated with only chemotherapy. No benefits of reoperation were observed in the univariate analysis. Conclusion: The second surgery in recurrent GBM has limited effect in clinical course.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow